Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avidity Biosciences ( (RNA) ) has shared an announcement.
On February 23, 2026, Avidity Biosciences, Inc. announced that it would open its special meeting of stockholders scheduled for that day and immediately adjourn it, reconvening on February 26, 2026 via the same virtual link. The adjournment is intended to allow more time to satisfy conditions for the pro rata distribution of all Atrium Therapeutics, Inc. shares to Avidity stockholders, a prerequisite for the company’s proposed merger with Novartis AG.
Avidity said it expected the Atrium Therapeutics distribution to occur on February 26, 2026 and the merger with Novartis to close on February 27, 2026, with both steps still subject to customary closing conditions including shareholder approvals. To facilitate the distribution and a transition of its stock in connection with the merger, Avidity’s shares are set to trade temporarily on the Nasdaq Global Market under the symbol “RNAM,” while previously submitted proxies and the January 29, 2026 record date remain valid for the reconvened meeting.
The most recent analyst rating on (RNA) stock is a Hold with a $72.00 price target. To see the full list of analyst forecasts on Avidity Biosciences stock, see the RNA Stock Forecast page.
Spark’s Take on RNA Stock
According to Spark, TipRanks’ AI Analyst, RNA is a Neutral.
The overall stock score reflects a mix of strong technical momentum and positive corporate events, particularly the merger with Novartis, which is a major strategic development. However, financial performance challenges, including negative profitability and cash flow, weigh on the score. The valuation reflects typical biotech growth characteristics, with a focus on future potential rather than current earnings.
To see Spark’s full report on RNA stock, click here.
More about Avidity Biosciences
Avidity Biosciences, Inc. is a San Diego-based biopharmaceutical company focused on a new class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs). Its proprietary AOC platform aims to combine monoclonal antibody specificity with oligonucleotide precision to target diseases that have been difficult to treat with existing RNA therapies, including rare muscle diseases and genetic cardiomyopathies.
The company has demonstrated targeted RNA delivery into muscle and is advancing clinical programs in myotonic dystrophy type 1, Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy. Avidity is also developing precision cardiology candidates for rare cardiomyopathies and expanding into cardiology and immunology indications through partnerships, positioning itself as a leading innovator in next-generation RNA medicines.
Average Trading Volume: 2,143,676
Technical Sentiment Signal: Buy
Current Market Cap: $11.27B
For an in-depth examination of RNA stock, go to TipRanks’ Overview page.